WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

Bis zum lunchbreak: Hang Seng Index soars 348 points in half a day https://www2.hkej.com/landing/mobArticle2/id/2672869 The blue chips are generally doing well. ...WuXi Biologics ( 02269 ) rose 3.2%;  ... HSI  Once Widens Upswing to Over 300 Pts to Surpass 26,900; Mengniu, Wuxi Bio Bust Peaks http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02269/RUM.201230_102554/hk-stock-news

[Closing summary] Science and technology companies rebounded to help the index once returned to 8,000, the HSI closed up 253 points https://hd.stheadline.com/amp/news/realtime/fin/1962468/ ...Blue chip stocks are improving. AIA (01299), Anta (02020), Mengniu (02319) and WuXi Biologics (02269) all set new listing highs. Unfortunately, profit-taking pressure increased after the top break, U-turns fell, and restrictions were imposed. ...

Yamato: Pharmaceutical stocks continue to prefer Kangfang Bio, WuXi Biologics, and Zhongsheng Pharmaceutical under policy pressure https://wap.eastmoney.com/a/202012291755188911.html ... WuXi Biologics (2269.HK) is the bank's top choice for large-cap stocks and pharmaceutical research and development outsourcing (CRO) drugs , which has risen 57% in the past two and a half months. Benefited from the public health incident, the group has obtained more than 20 related projects, and it is believed that most of the revenue will be recorded in 2021. The new strategy "winning the molecule" has won 10 projects for it. It is believed that the group has room for further development. The target price is HK$100 and the rating is "Buy". ...

The top ten gains in 2020 Hong Kong stocks Buffett has invested in the "strongest Hong Kong stocks" which has risen 7 times in one year, and the trend has been soaring! https://www.edigest.hk/%e6%8a%95%e8%b3%87/2020%e5%b9%b4-%e5%8d%81%e5%a4%a7%e5%8d%87%e5%b9%85-%e6%b8%af%e8%82%a1-%e5%b7%b4%e8%8f%b2%e7%89%b9-%e9%83%bd%e6%9c%89%e6%8a%95%e8%b3%87-%e6%9c%80%e5%bc%b7%e6%b8%af%e8%82%a1-%e4%b8%80%e5%b9%b4%e5%8d%87-223159/ There are still a few days before 2021. Looking back on the performance of Hong Kong stocks in 2020, the Hang Seng Index reached a high of 29,174 points and a low of 21,139 points. This year's main board of the Hong Kong stock market saw the strongest gains from Wuling Automobile (00305). Among the constituent stocks of the Hang Seng Index, WuXi Biologics (02269) has gained the most, up 193% so far this year; followed by Xiaomi (01810). ...

WuXi Biologics Receives GMP Certification from Brazil's ANVISA https://www.prnewswire.com/news-releases/wuxi-biologics-receives-gmp-certification-from-brazils-anvisa-301198586.html First company in China to receive GMP certification for the production of biologics from the U.S. FDA, EMA and ANVISA ...

Der Bericht ist relativ lang. Für die Ausführungen zu Wuppertal + Leverkusen vielleicht einfach selbst durch den Übersetzer jagen. Betrifft großteils die Kapazitäten und Kosten. BOC International raises target price of Wuxi Biologics (02269-HK) to HK$105, maintain Buy https://www.finet.hk/newscenter/news_content/5fe92e2cbde0b30d4618df77 Bank of China International released a report that Wuxi Biologics (02269-HK) had a target price of HK$105 and maintained its buy. ... Wuppertal... Leverkusen... The two production plants are expected to be put into production in 2021, providing strong support for the Group's European production supply chain. In addition, these transactions are a key part of the Group's strategy of "WuXi Biologics provides global dual-factory production", which can generate strong synergies with its existing production capacity and continue to provide high-quality and efficient production services.

Hong Kong News Financial Review: The times make science and technology king, and the index transformation is a matter of course-Hong Kong Economic Journal, December 24 https://www.reuters.com/article/%E6%B8%AF%E6%8A%A5%E8%B4%A2%E7%BB%8F%E8%AF%84%E8%AE%BA%EF%BC%9A%E6%97%B6%E5%8A%BF%E9%80%A0%E5%B0%B1%E7%A7%91%E6%8A%80%E4%B8%BA%E7%8E%8B%EF%BC%8C%E6%8C%87%E6%95%B0%E8%BD%AC%E5%9E%8B%E9%A1%BA%E7%90%86%E6%88%90%E7%AB%A0-%E4%BF%A1%E6%8A%A512%E6%9C%8824%E6%97%A5-idCNL4S2J401O ... On September 7 this year, the Hang Seng Index added 3 newcomers, all from the technology industry, namely Xiaomi, WuXi Biologics (02269) and Alibaba. Since that day, the HSI has risen 1648 points. Xiaomi and WuXi Contributed 475 points of increase, equivalent to 29% of the increase during the index period. ...

https://myemail.constantcontact.com/Holiday-Greeting--Together-We-Made-a-Difference---Message-from-Chris-Chen--CEO---WuXi-Biologics.html?soid=1130278665456&aid=EfzVOt0fErE

https://www.presseportal.de/pm/133071/4798562

Vermutlich in deinem Depot? Denn Hongkong leuchtet aktuell rot.

Schon 10% up. Prima :)

Credit Suisse: WuXi Biologics target price raised to HK$107 to maintain outperform rating https://finance.sina.cn/hkstock/ggpj/2020-12-23/detail-iiznezxs8433776.d.html?from=wap ...Plant DP7 shows WuXi Biologics' determination to expand globally. It is expected that the two plants will be put into operation in 2021. According to the bank, WuXi Biologics expects that under the influence of public health events, sales in 2021 will increase by 50% year-on-year, and in fiscal 2022, it will increase by 40% to 50%. It is expected that the purchase restriction will help it increase profitability in the medium and long term. ability. The recent strong performance of WuXi’s share price. Credit Suisse believes that it may be due to the improved atmosphere of the new round of negotiations on the National Medical Insurance Drug Catalog, which has driven the entire sector to rise. Taking into account the adjustment of short-term earnings forecasts, the earnings per share forecast for this year has been lowered by 1.3%. We will also raise the earnings per share estimates for 2021-2022 by 5.3% and 4.6%, and raise the target price by 23.4% from HK$86.67 to HK$107. Maintain the “Outperform” rating and believe that the demand for R&D outsourcing business is strong.

C  Suisse Hikes WUXI BIO (02269.HK) TP to HK$107, Rated Outperform http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02269/NOW.1064873/hk-stock-news WUXI  BIO plans to buy Bayer's biologics drug substance manufacturing facility asset (MFG19) in Germany at EUR150 million. Together with the German manufacturing plant (DP7) acquired from Bayer in April, these two deals showed WUXI BIO's determination for global expansion, opined Credit Suisse. WUXI BIO  BIO was kept at Outperform, with target lifted from $86.67 to $107.

WuXi läuft immer besser und ich bleibe dabei, dass es hier ein riesengroßes Potenzial gibt😊👍🏼

Der Hang Seng Index schloss bei 26.119 Punkten, ein Minus von 187 Punkten, der Hang Seng Technology Index schloss bei 8.186 Punkten, ein Plus von 26 Punkten, und Guangdong Investment stieg um mehr als 11%. WuXi Biologics und WuXi AppTec verzeichneten einen hohen Umsatz http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1064678/2

Looking to build a 'dual sourcing' supply chain, WuXi Biologics shells out $183M for Bayer drug substance plant https://endpts.com/looking-to-build-a-dual-sourcing-supply-chain-wuxi-biologics-shells-out-183m-for-bayer-drug-substance-plant/